Immuno-oncology
Conference Coverage
Early results favorable for combo TLR9 agonist + pembro in advanced melanoma
CHICAGO – The combination of pembrolizumab with CMP-001 is being evaluated as a strategy to overcome resistance to PD-1 blockade for patients with...
Conference Coverage
KEYNOTE-054: Adjuvant pembrolizumab beat placebo in high-risk resected melanoma
CHICAGO – One-year rates of recurrence-free survival for adjuvant pembrolizumab and placebo were 75% and 61%, respectively, in a phase 3 trial of...
From the Journals
Blinatumomab triggers complete MRD response in ALL
Complete MRD response was associated with improved relapse-free and overall survival.
Conference Coverage
Surgery after immunotherapy effective in advanced melanoma
CHICAGO – Five-year survival was 75% in selected patients with advanced melanoma who had resection to no evidence of disease after immunotherapy...
Conference Coverage
Checkpoint inhibition less toxic than antiangiogenic therapy in NSCLC
ORLANDO – Checkpoint blockade associated with less combined direct and indirect toxicity, a systematic review and meta-analysis suggests.
From the Journals
Nivolumab helps some with advanced NSCLC reach 5-year mark
For 129 patients with previously treated advanced non-small cell lung cancer, the estimated 5-year overall survival rate was 16%.
Conference Coverage
HDAC inhibition may boost immune therapy efficacy in breast cancer
ORLANDO – Entinostat and nivolumab with or without ipilimumab showed encouraging activity in early results from a phase 1 trial of patients with...
Conference Coverage
Chemotherapy, metabolic pathway may affect CAR T-cell potential
Chemotherapy, especially with cyclophosphamide and doxorubicin, seems particularly toxic to T cells.
Latest News
Cancer groups offer guidance on immune-related adverse events
Both ASCO and NCCN have released guidelines with tips for managing the side effects of cancer immunotherapy agents.
From the Journals
DNA repair gene mutations predict response to anti–PD-1/PD-L1 in urothelial cancer
Patients with any DDR gene mutations were more likely to have a clinical response to anti–PD-1/PD-L1 therapy.
From the Journals
Avelumab safety compares with other checkpoint inhibitors
Although about two-thirds of patients had treatment-related adverse events, most experienced only mild or moderate ones.